keyword
MENU ▼
Read by QxMD icon Read
search

RCC

keyword
https://www.readbyqxmd.com/read/27913534/myelodysplastic-and-myeloproliferative-disorders-of-childhood
#1
Henrik Hasle
Myelodysplastic syndrome (MDS) and myeloproliferative disorders are rare in children; they are divided into low-grade MDS (refractory cytopenia of childhood [RCC]), advanced MDS (refractory anemia with excess blasts in transformation), and juvenile myelomonocytic leukemia (JMML), each with different characteristics and management strategies. Underlying genetic predisposition is recognized in an increasing number of patients. Germ line GATA2 mutation is found in 70% of adolescents with MDS and monosomy 7. It is challenging to distinguish RCC from aplastic anemia, inherited bone marrow failure, and reactive conditions...
December 2, 2016: Hematology—the Education Program of the American Society of Hematology
https://www.readbyqxmd.com/read/27909997/saururus-chinensis-baill-inhibits-proliferation-and-invasion-of-human-renal-cell-carcinoma-cells-through-inhibition-of-inhibitor-of-apoptosis-protein
#2
Yong Hyun Park, Jung-In Kim, Su Yeon Seo, Eunhye Lee, Hyeon Hoe Kim
OBJECTIVE: To investigate the inhibitory effect of Saururus chinensis Baill on cell viability, apoptosis, invasion capacity and the mechanism involved in human renal cell carcinoma (RCC) cells. METHODS: After treating A498 and ACHN cells with Saururus chinensis Baill extract (0, 25, 50 μg/mL), inhibitory effect of Saururus chinensis Baill were evaluated using tetrazolium salt-based colorimetric assay, flfl ow cytometry analysis, and in vitro Matrigel invasion assay, respectively...
December 1, 2016: Chinese Journal of Integrative Medicine
https://www.readbyqxmd.com/read/27909994/cabozantinib-a-review-in-advanced-renal-cell-carcinoma
#3
Zaina T Al-Salama, Gillian M Keating
The multiple tyrosine kinase inhibitor (TKI) cabozantinib (Cabometyx™) is approved in the USA for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior antiangiogenic therapy. In the EU, cabozantinib is indicated for the treatment of advanced RCC in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy. In adults with advanced or metastatic clear-cell RCC who had previously received VEGF receptor (VEGFR) TKIs, progression-free survival (PFS) and overall survival (OS) were significantly prolonged in patients who received oral cabozantinib versus oral everolimus in the pivotal METEOR trial...
December 1, 2016: Drugs
https://www.readbyqxmd.com/read/27909903/obesity-and-kidney-cancer
#4
Kathryn M Wilson, Eunyoung Cho
Renal cell cancer (RCC) is the major type of kidney cancer with increasing incidence. Obesity is one of the well-established risk factors for RCC. Meta-analyses including multiple cohort and case-control studies have found a consistent positive association between obesity and RCC. The association appeared to be independent of other RCC risk factors including hypertension and has been often stronger in women, although a positive association has also been observed in men. Obesity has been largely measured as body mass index (BMI)...
2016: Recent Results in Cancer Research
https://www.readbyqxmd.com/read/27908730/mtor-activation-is-critical-for-betulin-treatment-in-renal-cell-carcinoma-cells
#5
Wenlong Cheng, Shiqi Ji, Haijian Zhang, Zhixing Han, Qingjun Liu, Jianwen Wang, Hao Ping
Betulin, a natural product isolated from the bark of the birch trees, exhibits multiple anticancer effects. Activation of mTOR signaling pathway has been found in numerous cancers, including renal cell carcinoma (RCC). Here, we attempted to study whether mTOR signaling was essential for betulin to treat RCC. Based on cell survival and colony formation assays, we found that mTOR hyperactive RCC cell line 786-O cells were more sensitive to betulin treatment compared with mTOR-inactive Caki-2 cells. Knockdown of TSC2 in Caki-2 cells had similar results to 786-O cells, and mTOR silencing in 786-O cells rescued the inhibitory effect of betulin, indicating that betulin inhibited RCC cell proliferation in an mTOR-dependent manner...
November 28, 2016: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/27907930/microrna-profiling-in-clear-cell-renal-cell-carcinoma-tissues-potentially-links-tumorigenesis-and-recurrence-with-obesity
#6
X Shu, M A Hildebrandt, J Gu, N M Tannir, S F Matin, J A Karam, C G Wood, X Wu
BACKGROUND: Twenty to 40% localised RCC patients may experience recurrence after curative surgery. Limited miRNA predictors have been identified for ccRCC recurrence. METHODS: Through a multi-phase study design, we analysed miRNAs in tissues obtained from 203 ccRCC patients. Paired t-test was used for tumour-normal comparisons and Cox regression model was performed to compute hazard ratios (HRs) and corresponding 95% CIs. RESULTS: A 17-miRNA signature was identified that can concordantly classify >95% of tumour/adjacent normal samples...
December 1, 2016: British Journal of Cancer
https://www.readbyqxmd.com/read/27907929/critical-evaluation-of-the-potential-prognostic-value-of-the-pretreatment-derived-neutrophil-lymphocyte-ratio-under-consideration-of-c-reactive-protein-levels-in-clear-cell-renal-cell-carcinoma
#7
Orietta Dalpiaz, Theresa Luef, Maximilian Seles, Michael Stotz, Tatjana Stojakovic, Karl Pummer, Richard Zigeuner, Georg C Hutterer, Martin Pichler
BACKGROUND: We investigated the prognostic value of the pretreatment-derived neutrophil-lymphocyte ratio (dNLR) and original NLR in relation to the commonly used inflammation marker C-reactive protein (CRP) in a large cohort of patients with clear cell renal cell carcinoma (RCC). METHODS: Clinicopathological data from 587 consecutive non-metastatic clear cell RCC patients, operated between 2000 and 2010 at a single tertiary academic center, were evaluated retrospectively...
December 1, 2016: British Journal of Cancer
https://www.readbyqxmd.com/read/27906674/nuclear-localization-of-the-ck2%C3%AE-subunit-correlates-with-poor-prognosis-in-clear-cell-renal-cell-carcinoma
#8
Maj Rabjerg, Barbara Guerra, Aida Oliván-Viguera, Minne Line Nedergaard Mikkelsen, Ralf Köhler, Olaf-Georg Issinger, Niels Marcussen
Protein kinase CK2α, one of the two catalytic isoforms of the protein kinase CK2 has been shown to contribute to tumor development, tumor proliferation and suppression of apoptosis in various malignancies. We conducted this study to investigate CK2 expression in different subtypes of Renal Cell Carcinoma (RCC) and in the benign oncocytoma. qRT-PCR, immunohistochemistry and Western blot analyses revealed that CK2α expression was significantly increased at the mRNA and protein levels in clear cell RCC (ccRCC)...
November 29, 2016: Oncotarget
https://www.readbyqxmd.com/read/27904651/sunitinib-in-the-treatment-of-metastatic-renal-cell-carcinoma
#9
REVIEW
Thomas A Schmid, Martin E Gore
Sunitinib is an oral multi-targeted tyrosine kinase inhibitor (TKI) that targets various receptors, including vascular endothelial growth factor receptors (VEGFRs). Sunitinib received approval in 2006 and became a standard treatment option in the first-line treatment of metastatic renal cell cancer (mRCC) after a phase III trial showed superiority compared with interferon alpha (IFN-α). Sunitinib has also shown activity in second-line treatment in several trials. Most of the combination trials with sunitinib with various agents have led to considerable toxicity without improving efficacy...
December 2016: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/27904650/cabozantinib-in-the-treatment-of-advanced-renal-cell-carcinoma-clinical-trial-evidence-and-experience
#10
REVIEW
Jose Manuel Ruiz-Morales, Daniel Y C Heng
The treatment of metastatic renal cell carcinoma (mRCC) is rapidly changing. During first-line treatment with targeted therapy, patients ultimately develop resistance to therapy and the disease progresses. Recently, cabozantinib has demonstrated a better response rate, progression-free survival and overall survival compared with everolimus after failure of prior targeted therapy in patients with advanced or metastatic renal cell carcinoma (RCC). Cabozantinib is a small-molecule tyrosine kinase inhibitor (TKI)...
December 2016: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/27903081/percutaneous-microwave-ablation-of-renal-cell-carcinoma-is-safe-in-patients-with-renal-dysfunction
#11
Yan Lin, Ping Liang, Xiao-Ling Yu, Jie Yu, Zhi-Gang Cheng, Zhi-Yu Han, Fangyi Liu
OBJECTIVES: To present the clinical effect of microwave ablation(MWA) on renal cell carcinoma(RCC) of the patients with renal dysfunction, mainly focusing on the extent of renal tumor control and damage to the residual kidney function. METHODS AND MATERIALS: From 2006 to 2014, 19 tumors of 18 patients with renal dysfunction underwent percutaneous ultrasound-guided MWA in our institution. The tumor diameters range from 1.9 to 5.0cm. The serum creatinine and urea levels of each patient pre-MWA, 1 day after MWA and the most recent occasion on record at our institution were collected...
November 30, 2016: International Journal of Hyperthermia
https://www.readbyqxmd.com/read/27900012/ubenimex-enhances-the-radiosensitivity-of-renal-cell-carcinoma-cells-by-inducing-autophagic-cell-death
#12
Shuai Liu, Xiaoqing Wang, Jiaju Lu, Liping Han, Yongfei Zhang, Zheng Liu, Sentai Ding, Zhao Liu, Dongbin Bi, Zhihong Niu
Renal cell carcinoma (RCC) is resistant to standard radiotherapy. Ubenimex, an aminopeptidase N inhibitor, is widely used as an adjunct therapy after surgery to enhance the function of immunocompetent cells and confer antitumor effects. Our previous study demonstrated that ubenimex induces autophagic cell death in RCC cells. Recently, the molecular mechanism of autophagy induction has been associated with radiosensitivity in RCC cells. In the present study, the ability of ubenimex to enhance RCC cell sensitivity to radiation via the induction of autophagic cell death was determined, and the mechanism of action of this effect was investigated...
November 2016: Oncology Letters
https://www.readbyqxmd.com/read/27899986/metastasis-of-renal-cell-carcinoma-to-the-parathyroid-gland-16-years-after-radical-nephrectomy-a-case-report
#13
Liborio Torregrossa, Maria Isabella Rotondo, Andrea Cacciato Insilla, David Galleri, Federica Guidoccio, Paolo Miccoli, Virginia A Livolsi, Fulvio Basolo
Renal cell carcinoma (RCC) has a high metastatic potential, and most commonly metastasizes via the bloodstream, although lymphatic metastases also occur. RCC is well-known for its propensity to metastasize to unusual sites, and late metastasis, even after a number of years, is common. The occurrence of RCC metastasis to the head and neck region is uncommon, and occurs primarily in the thyroid gland and in patients with widespread dissemination. Involvement of the parathyroid gland in metastatic carcinoma is extremely rare...
November 2016: Oncology Letters
https://www.readbyqxmd.com/read/27899189/genetic-predisposition-to-kidney-cancer
#14
REVIEW
Laura S Schmidt, W Marston Linehan
Kidney cancer is not a single disease but is made up of a number of different types of cancer classified by histology that are disparate in presentation, clinical course, and genetic basis. Studies of families with inherited renal cell carcinoma (RCC) have provided the basis for our understanding of the causative genes and altered metabolic pathways in renal cancer with different histologies. Von Hippel-Lindau disease was the first renal cancer disorder with a defined genetic basis. Over the next two decades, the genes responsible for a number of other inherited renal cancer syndromes including hereditary papillary renal carcinoma, Birt-Hogg-Dube´syndrome, hereditary leiomyomatosis and renal cell carcinoma, and succinate dehydrogenase-associated renal cancer were identified...
October 2016: Seminars in Oncology
https://www.readbyqxmd.com/read/27896403/histology-is-a-prognostic-indicator-after-pulmonary-metastasectomy-from-renal-cell-carcinoma
#15
Yoichi Ohtaki, Kimihiro Shimizu, Keiju Aokage, Masayuki Nakao, Junji Yoshida, Mitsuhiro Kamiyoshihara, Masayuki Sugano, Yusuke Takahashi, Seshiru Nakazawa, Toshiteru Nagashima, Kai Obayashi, Tomoyuki Hishida, Masahiro Tsuboi, Shohei Mori, Mingyon Mun, Sakae Okumura, Hitoshi Igai, Noriyuki Matsutani, Akira Mogi, Hiroyuki Kuwano
OBJECTIVES: There are only a few detailed reports concerning the prognosticators following surgical resection of pulmonary metastases (PMs) from renal cell carcinoma (RCC). We investigated the prognosis of patients with RCC PMs undergoing pulmonary metastasectomy and identified prognostic factors in a multi-institutional retrospective study. METHODS: We retrospectively evaluated 84 patients who underwent resection of PMs from RCC between 1993 and 2014. We assessed the clinicopathological characteristics, focusing on the histological findings of PMs...
November 28, 2016: World Journal of Surgery
https://www.readbyqxmd.com/read/27896135/thrombus-like-tumor-of-renal-cell-carcinoma-mimicking-transitional-cell-carcinoma-of-kidney-a-case-report
#16
Dyandra Parikesit, Chaidir A Mochtar, Budiana Tanurahardja, Sahat Matondang, Rainy Umbas, Agus Rizal Hamid
Renal cell carcinoma (RCC) is the most common malignancy of the kidney. It is not commonly form tumor thrombus in the ureter or renal pelvis. A 29-year-old woman presented with asymptomatic gross hematuria. Contrast CT study revealed a tumor suspected to be a Transitional Cell Carcinoma (TCC). However, tumor thrombus was found in the renal pelvis and ureter. We performed Nephroureterectomy, bladder cuff excision, and lymph node dissection, and the tumor was diagnosed histopathologically as RCC. We report a very rare case of thrombus-like tumor of renal cell carcinoma mimicking transitional cell carcinoma of kidney...
January 2017: Urology Case Reports
https://www.readbyqxmd.com/read/27895977/hepatitis-c-infection-and-renal-cell-carcinoma-a-systematic-review-and-meta-analysis
#17
Karn Wijarnpreecha, Pitchaphon Nissaisorakarn, Suthanya Sornprom, Charat Thongprayoon, Natanong Thamcharoen, Kunlatida Maneenil, Alexander J Podboy, Wisit Cheungpasitporn
AIM: To investigate the association between hepatitis C virus (HCV) infection and risk of renal cell carcinoma (RCC). METHODS: A literature search was performed from inception until February 2016. Studies that reported relative risks, odd ratios, hazard ratios or standardized incidence ratio comparing the risk of RCC among HCV-infected participants vs those without HCV infection were included. Participants without HCV infection were used as comparators. Pooled odds ratios and 95%CI were calculated using a random-effect, generic inverse variance method...
November 15, 2016: World Journal of Gastrointestinal Pathophysiology
https://www.readbyqxmd.com/read/27895733/improved-laparoscopic-nephron-sparing-surgery-for-renal-cell-carcinoma-based-on-the-precise-anatomy-of-the-nephron
#18
Gang Guo, Wei Cai, Xu Zhang
The aim of the present study was to investigate a method of laparoscopic nephron-sparing surgery (LNSS) for renal cell carcinoma (RCC) based on the precise anatomy of the nephron, and to decrease the incidence of hemorrhage and urinary leakage. Between January 2012 and December 2013, 31 patients who presented to the General Hospital of the People's Liberation Army (Beijing, China) were treated for RCC. The mean tumor size was 3.4±0.7 cm in diameter (range, 1.2-6.0 cm). During surgery, the renal artery was blocked, and subsequently, an incision in the renal capsule and renal cortex was performed, at 3-5 mm from the tumor edge...
November 2016: Oncology Letters
https://www.readbyqxmd.com/read/27894094/met-expression-and-copy-number-status-in-clear-cell-renal-cell-carcinoma-prognostic-value-and-potential-predictive-marker
#19
Stephan Macher-Goeppinger, Martina Keith, Volker Endris, Roland Penzel, Katrin E Tagscherer, Sascha Pahernik, Markus Hohenfellner, Humphrey Gardner, Carsten Grüllich, Peter Schirmacher, Wilfried Roth
Multiple targeted therapy for advanced clear-cell renal cell carcinoma (RCC) has substantially improved patient outcome, but complete remission is uncommon and many tumors eventually develop resistance. Mechanistic, preclinical, and early clinical data highlight c-Met / hepatocyte growth factor receptor as a promising target for RCC therapeutic agents.We have examined MET expression, frequency of MET gene copy gains and MET gene mutation in a large, hospital-based series of renal cell carcinomas with long-term follow-up information...
November 24, 2016: Oncotarget
https://www.readbyqxmd.com/read/27891445/breast-cancer-with-synchronous-renal-cell-carcinoma-a-rare-presentation
#20
Ravi Arjunan, Durgesh Kumar, K V Veerendra Kumar, C S Premlatha
Primary cancer arising from multiple organs is a well known fact. Synchronous tumours have been most commonly associated with kidney cancer. Bladder, prostate, colorectal and lung cancer are the most common synchronous primaries with Renal Cell Carcinoma (RCC) identified till date. We found metachronous tumours of breast with RCC in literature search which included both metastatic tumours as well second primaries. Overall, 25 cases of metastatic breast tumours and eight cases of second primary in previously treated RCC have been reported in the literature...
October 2016: Journal of Clinical and Diagnostic Research: JCDR
keyword
keyword
10482
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"